Perceptive Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Perceptive Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-960,000	Closed	-$109M	–	115
2022 Q4	$109M	Buy	+960,000	New	+$79.7M	3.07%	7
2022 Q2	–	Sell	-1,357,903	Closed	-$143M	–	142
2022 Q1	$143M	Sell	1,357,903 -380,237	-22%	-$37.1M	2.86%	9
2021 Q4	$187M	Sell	1,738,140 -218,800	-11%	-$23.9M	2.89%	7
2021 Q3	$214M	Sell	1,956,940 -28,062	-1%	-$2.91M	3.11%	8
2021 Q2	$186M	Sell	1,985,002 -65,000	-3%	-$5.98M	2.41%	8
2021 Q1	$189M	Sell	2,050,002 -1,034,040	-34%	-$87.3M	2.39%	11
2020 Q4	$226M	Buy	+3,084,042	New	+$229M	2.42%	9
2016 Q2	–	Sell	-350,000	Closed	-$5.8M	–	219
2016 Q1	$5.8M	Buy	+350,000	New	+$6.12M	0.51%	50
2014 Q2	–	Sell	-9,120	Closed	-$138K	–	157
2014 Q1	$138K	Buy	+9,120	New	+$103K	0.01%	116

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Perceptive Advisors's HZNP Position: Q1 2023 in Review

Perceptive Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 960,000 shares — an estimated $109M sold.

Perceptive Advisors first reported a position in HZNP in Q1 2014 and held it in 9 quarters. The position peaked at $226M in Q4 2020. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Perceptive Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Perceptive Advisors sold 960,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $109M.
Perceptive Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2014 and held it in 9 quarters.
Perceptive Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $226M in Q4 2020.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Perceptive Advisors's 13F filing for Q1 2023, filed 15 May 2023.